Ftse Mib
33.308,77
-1,09%
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
NASDAQ
17.689,36
-0,18%
Bitcoin
64.068,22
-0,28%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Tenax Therapeutics Inc (TENX) Tenax Therapeutics Inc (TENX) Notizie

Tenax Therapeutics Inc

TENX
2,90
-0,13 (-4,29%)
22 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/6/202422:32EDGAR2Form 8-K - Current report
24/5/202422:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/5/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202415:01EDGAR2Form 8-K - Current report
14/5/202414:00GLOBETenax Therapeutics Reports First Quarter 2024 Financial..
30/4/202413:30GLOBETenax Therapeutics Announces New U.S. Patent Covering the..
09/4/202414:30GLOBETenax Therapeutics to Host KOL Event: “LEVEL Setting: the..
28/3/202413:30GLOBETenax Therapeutics Provides Business and Clinical..
12/3/202413:30GLOBETenax Therapeutics to Present at the 36th Annual Roth..
29/2/202415:00GLOBETenax Therapeutics Announces Oral Presentation of..
23/2/202422:30EDGAR2Form 8-K - Current report
20/2/202422:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20/2/202414:33EDGAR2Form 8-K - Current report
20/2/202414:30GLOBETenax Therapeutics Announces Global License Amendment that..
16/2/202417:28EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/2/202401:36EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202422:46EDGAR2Form 8-K - Current report
08/2/202414:16GLOBETenax Therapeutics Announces Pricing of Approximately $9..
08/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
08/2/202402:01GLOBETenax Therapeutics Enrolls First Patient in Phase 3 LEVEL..
06/2/202414:56EDGAR2Form 8-K - Current report
06/2/202414:30GLOBETenax Therapeutics Announces USPTO Grants Notice of..
02/2/202423:24EDGAR2Form S-1/A - General form for registration of securities..
01/2/202422:20EDGAR2Form S-1/A - General form for registration of securities..
19/1/202422:30EDGAR2Form 8-K - Current report
12/1/202423:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/1/202422:30EDGAR2Form 8-K - Current report
05/1/202422:46EDGAR2Form 8-K - Current report
01/12/202322:47EDGAR2Form S-1 - General form for registration of securities under..
01/12/202322:01EDGAR2Form 8-K - Current report
17/11/202314:30GLOBETenax Therapeutics Announces Professor Javed Butler, M.D.,..
14/11/202322:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/11/202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202315:10EDGAR2Form 8-K - Current report
13/11/202314:30GLOBETenax Therapeutics Announces FDA Clearance of IND for..
29/9/202322:11EDGAR2Form 8-K - Current report
15/8/202322:05EDGAR2Form 8-K - Current report
14/8/202322:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
19/7/202322:30EDGAR2Form 8-K - Current report
19/7/202314:30GLOBETenax Therapeutics Issued U.S. Patent for Oral Levosimendan..
Apertura: 3,09 Min: 2,82 Max: 3,09
Chiusura: 3,03

La tua Cronologia

NASDAQ
TENX
Tenax Therapeutics
LSE
NABB
Nationwide.pibs
UNSW3
CENNZETH
Centrality Token
USOTC
BKGFY
Berkeley (PK)
EU
FR0014004TJ7
Pixel 2021 Pixelffrn28fe...
USOTC
BYIN
Baying Ecological (GM)
NASDAQ
PSCF
Invesco S&P SmallCap Fin...
AMEX
HVO.X
LSE
OT3
Oxford Technology 2 Vent...
LSE
SJ58
Boi Fin.27
TG
CAI
Canadian Imperial Bank O...
NASDAQI
OMXSSESGNI
OMX Sweden Small Cap ESG...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network